Cellink taps into healthcare demand with $109m share sale

Aidan Gregory

August 20, 2020 09:00 am

Cellink_PA_575_375 — (190416)-- TEL AVIV, April 16, 2019 (Xinhua) Photo taken on April 15, 2019 shows a 3D-printed heart with human tissue at the University of Tel Aviv in Israel. Tel Aviv University scientists said on Monday that they have printed the first 3D heart, by using patient's cells and materials. The heart, which was produced in a lab, completely matches the biological characteristics of the patient's heart. It took about three hours to print the whole heart. Making a human heart model is a major medical breakthrough. However, the printed vascularized and engineered heart is approximately 100 times smaller than a real human heart. TO GO WITH "Feature: Israeli scientists use 3D printing to create world's 1st model of human heart" (Xinhua/JINI/Gideon Markowicz) | Gideon Markowicz/Xinhua News Agency/PA Images

Shares in Cellink, the Swedish maker of 3D printing equipment for the life sciences industry, rose more than 4% on Thursday morning after the company completed a Skr946m ($109.2m) growth capital raising, amid strong investor appetite for exposure to the healthcare sector due to the global Covid-19 pandemic.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request demo or Login

✔ 4,000 annual insights
✔ 700+ notes and long-form analyses
✔ 4 capital markets databases
✔ Daily newsletters across markets and asset classes
✔ 2 weekly podcasts

Topics

JP Morgan Nordics Sweden Equity ABBs-Block Trades Europe EMEA

AG

Aidan Gregory